Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunotherapy for superficial bladder cancer.

Ellen A M Schenk-Braat1, Chris H Bangma

  • 1Department of Urology, Josephine Nefkens Institute, Room Be 362, PO Box 1738, 3000, DR Rotterdam, The Netherlands. e.schenk-braat@erasmusmc.nl

Cancer Immunology, Immunotherapy : CII
|November 27, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improved prostate cancer grading by incorporating Gleason pattern quantification, invasive cribriform and intraductal carcinoma in the new QUICC-score.

Annals of diagnostic pathology·2026
Same author

Who, When, and How: Watchful Waiting in the ERSPC Rotterdam.

European urology open science·2026
Same author

Prostate cancer mortality among men with and without comorbidity: Long-term results from the European randomized study of screening for prostate cancer Rotterdam.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Cell-Based Immunization Combined with Single-Round Cell Panning Enables Discovery of PSMA-Targeting Nanobodies from Phage Display Libraries.

Biomolecules·2026
Same author

Targeted Prostate Cancer Screening in Carriers of BRCA1 or BRCA2 Pathogenic Germline Variants Detects Clinically Relevant Disease: 5-year Results from the IMPACT Study.

European urology·2026
Same author

Extending Current Guideline-recommended Prostate-specific Antigen Density Thresholds for Improving Benefit/Harm Balance in Risk-based Magnetic Resonance Imaging-directed Prostate Cancer Diagnosis, from the Community-based Multicentre MR-PROPER Study.

European urology oncology·2025
Same journal

Intracranially injected chimeric antigen receptor T cells eradicate glioblastoma cells but have limited potential to persist in the brain in a syngeneic mouse model.

Cancer immunology, immunotherapy : CII·2026
Same journal

Real-world treatment patterns and early outcomes in advanced intrahepatic cholangiocarcinoma: a descriptive case series.

Cancer immunology, immunotherapy : CII·2026
Same journal

CXCL13-CXCR5 signaling in CD8<sup>+</sup> T cell recruitment and lymphoid immune organization in clear cell renal cell carcinoma.

Cancer immunology, immunotherapy : CII·2026
Same journal

Conserved minimal CD8 cytotoxic immune-state unit in an IL18R1-associated immune program in hepatocellular carcinoma.

Cancer immunology, immunotherapy : CII·2026
Same journal

Safety and feasibility of 5T4 antibody-coupled allogeneic NK cell therapy for solid tumors: a first-in-human phase 1 trial.

Cancer immunology, immunotherapy : CII·2026
Same journal

Time-dependent cytokine landscapes in an ex vivo microfluidic glioblastoma platform.

Cancer immunology, immunotherapy : CII·2026
See all related articles

New immunotherapies offer a promising alternative for superficial bladder cancer treatment, addressing limitations of current chemotherapy and bacillus Calmette-Guérin therapies. These novel approaches aim to improve patient outcomes by modulating the immune system.

Area of Science:

  • Uro-oncology
  • Cancer Immunology
  • Adjuvant Cancer Therapy

Background:

  • Superficial bladder cancer has a high recurrence rate after transurethral resection.
  • Current adjuvant therapies like intravesical chemotherapy and bacillus Calmette-Guérin (BCG) have significant failure rates.
  • There is a critical need for novel and improved adjuvant treatment strategies.

Purpose of the Study:

  • To review the current clinical development status of various immunotherapy approaches for superficial bladder cancer.
  • To highlight immunotherapy as a promising alternative adjuvant therapy.
  • To discuss different immunotherapy modalities including passive immunotherapy, immune stimulants, immunogene therapy, and cancer vaccination.

Main Methods:

  • Literature review of clinical development in immunotherapy for superficial bladder cancer.

Related Experiment Videos

  • Analysis of current adjuvant treatment options and their limitations.
  • Discussion of emerging immunotherapy strategies.

    • Main Results:

    • Immunotherapy represents a promising avenue for superficial bladder cancer treatment.
    • Various immunotherapy approaches are under clinical investigation.
    • These include passive immunotherapy, immune stimulants, immunogene therapy, and cancer vaccination.

    Conclusions:

    • Immunotherapy holds significant potential as an alternative adjuvant treatment for superficial bladder cancer.
    • Further clinical development is crucial to overcome the limitations of existing therapies.
    • Modulating the patient's immune system offers a novel strategy for managing superficial bladder cancer.